Miguel Ruiz-Veguilla

Profesor Asociado

Universidad de Sevilla

Spain

Research Interests

Explore related searches

Professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Miguel Ruiz-Veguilla is an Asociado Professor at Universidad de Sevilla, Spain. His research focuses on the intersections of psychosis and metabolic syndrome, as well as the neurocognitive aspects of bipolar disorder and the implications of antipsychotic treatments during the COVID-19 pandemic. His recent publications include systematic reviews and meta-analyses exploring diagnostic stability and the effects of childhood adversities on psychotic symptoms.

Articles (10)

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (5)

Edoardo Spinazzola

King’s College London

UNITED KINGDOM

View details

Carlos Prieto

Head of Bioinformatics

Universidad de Salamanca

SPAIN

View details

Joan Vila Frances

Assistant professor

University of Valencia

SPAIN

View details

Juan L. Prados-Ojeda

Profesor Asociado

Universidad de Córdoba

SPAIN

View details

Esther Setién-Suero

Instituto de Investigación Marqués de Valdecilla

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Miguel Ruiz-Veguilla

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Is processing speed a valid neurocognitive endophenotype in bipolar disorder? Evidence from a longitudinal, family study

Metabolic syndrome in antipsychotic-naïve patients with first-episode psychosis: a systematic review and meta-analysis.

Metabolic syndrome in antipsychotic-naïve patients with first-episode psychosis: A systematic review and meta-analysis

Predictors of diagnostic stability in brief psychotic disorders: Findings from a 3-year longitudinal study.

Association Between Specific Childhood Adversities and Symptom Dimensions in People With Psychosis: Systematic Review and Meta-Analysis.

Comparison of aripiprazole and risperidone effectiveness in first episode non-affective psychosis: Rationale and design of a prospective, randomized, 3-phase, investigator-initiated study (PAFIP-3).

The role of antipsychotics against COVID-19: A topic for debate.

Clinical characterization of brief psychotic disorders triggered by the COVID-19 pandemic: a multicenter observational study.

Aripiprazole as a Candidate Treatment of COVID-19 Identified Through Genomic Analysis.

Prognostic significance of psychotic relapse in patients with first-episode acute and transient psychosis: New empirical support for ICD-11.

Collaborators (5)

Edoardo Spinazzola

Carlos Prieto

Joan Vila Frances

Juan L. Prados-Ojeda

Esther Setién-Suero

Make your next move.